SCHEMBL3006763

SCHEMBL3006763

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.45
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
AR P10275 1/20 0.38
GBA1 P04062 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003666 0.93 CTSS (0.45) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3005492 0.93 CTSS (0.45) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3000710 0.92 CTSS (0.45) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3014445 0.92 CTSS (0.47) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3015863 0.91 CTSS (0.44) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3013248 0.91 CTSS (0.44) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3013043 0.91 CTSS (0.45) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3015619 0.91 MAPT (0.47) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3014277 0.89 CTSS (0.44) CTSSKDM4EMAPTADORA2AADORA2B
SCHEMBL3007430 0.89 CTSS (0.44) CTSSKDM4EMAPTADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA CTSS 106/4885KDM4E 4398/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.